Neurocrine Biosciences, Inc. (NBIX)
169.40
-5.01
(-2.87%)
USD |
NASDAQ |
Nov 12, 16:00
169.47
+0.07
(+0.04%)
After-Hours: 20:00
Neurocrine Biosciences Market Cap : 17.16B for Nov. 12, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| November 12, 2026 | 17.16B |
| November 11, 2026 | 17.67B |
| November 10, 2026 | 17.13B |
| November 09, 2026 | 17.11B |
| November 06, 2026 | 16.68B |
| November 05, 2026 | 16.18B |
| November 04, 2026 | 16.82B |
| November 03, 2026 | 16.70B |
| November 02, 2026 | 14.72B |
| October 30, 2026 | 14.80B |
| October 29, 2026 | 14.83B |
| October 28, 2026 | 14.79B |
| October 27, 2026 | 14.83B |
| October 26, 2026 | 14.82B |
| October 23, 2026 | 14.50B |
| October 22, 2026 | 14.56B |
| October 21, 2026 | 14.36B |
| October 20, 2026 | 14.43B |
| October 19, 2026 | 13.92B |
| October 16, 2026 | 13.79B |
| October 15, 2026 | 13.91B |
| October 14, 2026 | 13.81B |
| October 13, 2026 | 13.73B |
| October 12, 2026 | 14.36B |
| October 09, 2026 | 14.47B |
| Date | Value |
|---|---|
| October 08, 2026 | 14.35B |
| October 07, 2026 | 14.58B |
| October 06, 2026 | 14.78B |
| October 05, 2026 | 14.65B |
| October 02, 2026 | 14.55B |
| October 01, 2026 | 14.30B |
| September 30, 2026 | 14.41B |
| September 29, 2026 | 14.06B |
| September 28, 2026 | 14.27B |
| September 25, 2026 | 14.06B |
| September 24, 2026 | 14.12B |
| September 23, 2026 | 14.17B |
| September 22, 2026 | 14.45B |
| September 21, 2026 | 14.63B |
| September 18, 2026 | 14.86B |
| September 17, 2026 | 15.43B |
| September 16, 2026 | 15.19B |
| September 15, 2026 | 15.24B |
| September 14, 2026 | 15.97B |
| September 11, 2026 | 15.87B |
| September 10, 2026 | 15.91B |
| September 09, 2026 | 15.76B |
| September 08, 2026 | 15.76B |
| September 04, 2026 | 15.81B |
| September 03, 2026 | 16.09B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| Amgen, Inc. | 252.63B |
| Halozyme Therapeutics, Inc. | 11.47B |
| BioCryst Pharmaceuticals, Inc. | 1.967B |
| Iovance Biotherapeutics, Inc. | 3.529B |
| Precigen, Inc. | 1.671B |
Market Cap Related Metrics
| PE Ratio | 25.12 |
| PS Ratio | 4.765 |
| PEG Ratio | 0.4112 |
| Price to Book Value | 4.424 |
| Price to Free Cash Flow | 18.13 |
| Price | 169.40 |
| Earnings Yield | 3.98% |
| PEGY Ratio | 0.4112 |
| Operating PE Ratio | 19.39 |
| Normalized PE Ratio | 23.39 |